{
    "ticker": "VIR",
    "name": "Vir Biotechnology, Inc.",
    "description": "Vir Biotechnology, Inc. is a clinical-stage immunology company focused on addressing and preventing serious infectious diseases. Founded in 2016 and headquartered in San Francisco, California, Vir's mission is to harness the power of the immune system to treat and prevent viral infections. The company is leveraging its expertise in monoclonal antibodies, T cell activation, and other immune-modulating technologies to develop therapies for a range of viral diseases, including COVID-19, influenza, and hepatitis B. Vir's lead product candidate, VIR-7831, is an investigational monoclonal antibody designed to treat COVID-19, and it has shown promise in clinical trials. In addition to its work on COVID-19, Vir is also developing therapies for other viral pathogens, aiming to provide innovative solutions to combat viral infections that are often resistant to current treatments. The company collaborates with various research institutions and pharmaceutical partners to advance its research and development efforts. Vir's commitment to scientific excellence and innovation positions it as a significant player in the biotechnology field, with the potential to make a lasting impact on public health.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2016",
    "website": "https://www.vir.bio",
    "ceo": "George Scangos",
    "social_media": {
        "twitter": "https://twitter.com/VirBiotechnology",
        "linkedin": "https://www.linkedin.com/company/vir-biotechnology"
    },
    "investor_relations": "https://ir.vir.bio",
    "key_executives": [
        {
            "name": "George Scangos",
            "position": "CEO"
        },
        {
            "name": "Alfred G. Gilman",
            "position": "Chairman"
        },
        {
            "name": "Lindsay A. Rosenwald",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "VIR-7831",
                "VIR-2218"
            ]
        }
    ],
    "seo": {
        "meta_title": "Vir Biotechnology, Inc. | Pioneering Immunology Solutions",
        "meta_description": "Explore Vir Biotechnology, Inc., a leader in immunology focused on developing therapies for serious infectious diseases like COVID-19 and hepatitis B.",
        "keywords": [
            "Vir Biotechnology",
            "COVID-19",
            "Immunology",
            "Biotechnology",
            "Monoclonal Antibodies",
            "Infectious Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does Vir Biotechnology focus on?",
            "answer": "Vir Biotechnology focuses on developing therapies for serious infectious diseases using advanced immunology techniques."
        },
        {
            "question": "Who is the CEO of Vir Biotechnology?",
            "answer": "George Scangos is the CEO of Vir Biotechnology, Inc."
        },
        {
            "question": "Where is Vir Biotechnology headquartered?",
            "answer": "Vir Biotechnology is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What are Vir's main products?",
            "answer": "Vir's main products include VIR-7831 for COVID-19 and VIR-2218 for hepatitis B."
        },
        {
            "question": "When was Vir Biotechnology founded?",
            "answer": "Vir Biotechnology was founded in 2016."
        }
    ],
    "competitors": [
        "MRNA",
        "PFE",
        "NVAX",
        "ABBV"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "BMY"
    ]
}